Lipid abnormalities in patients with chronic kidney disease: implications for the pathophysiology of atherosclerosis

Area of Science:

• Nephrology
• Cardiology
• Metabolic Disorders

Background:

• Cardiovascular disease (CVD) is the primary cause of death in chronic kidney disease (CKD) patients.
• In end-stage CKD, myocardial structural changes drive CVD, while atherosclerotic events cause 10-15% of CVD deaths.
• Dyslipidemia is prevalent in CKD, often presenting as high triglycerides and low high-density lipoprotein (HDL) levels, not necessarily high cholesterol.

Purpose of the Study:

• To investigate the characteristic lipid abnormalities in chronic kidney disease patients.
• To understand the impact of lipoprotein metabolism alterations on cardiovascular risk in CKD.
• To explore the role of apolipoprotein B and A metabolism in CKD-associated dyslipidemia.

Main Methods:

• Analysis of lipoprotein metabolism in CKD patients.
• Characterization of apolipoprotein B (apoB)-containing lipoproteins (apoB-48 and apoB-100) and their remnants.
• Evaluation of apolipoprotein A (apoA)-containing lipoprotein metabolism and HDL particle abnormalities.

Main Results:

• CKD patients exhibit common qualitative dyslipidemia with increased triglycerides and decreased HDL.
• Abnormalities in apoB-containing lipoprotein metabolism, including gut-derived (apoB-48) and hepatic (apoB-100) particles, lead to elevated atherogenic remnant levels.
• Altered apoA metabolism contributes to reduced HDL levels, and HDL particle abnormalities may promote inflammation and thrombosis in CKD.

Conclusions:

• Dyslipidemia in CKD is characterized by altered metabolism of apoB and apoA lipoproteins, contributing to increased cardiovascular morbidity and mortality.
• Reduced enzymatic delipidation and impaired receptor clearance of apoB lipoproteins increase atherogenic particle levels in CKD.
• Qualitative HDL abnormalities in CKD are linked to oxidative stress and a pro-inflammatory, pro-thrombotic state, exacerbating cardiovascular risk.